RCS - Arecor Therapeutics - APPOINTS DR. LINDSEY FOULKES AS COO

Arecor TherapeuticsAnnouncement

10/06/2021 07:05

RNS Number : 4040B
  
Arecor Therapeutics PLC
  
10 June 2021
  
 

 
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
 
 ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF OPERATING OFFICER
 
Cambridge, UK, 10 June 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today's therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company's Chief Operating Officer.
 
Lindsey brings a wealth of deep expertise and experience from the life science industry, with roles covering strategy, marketing, project management and corporate development. Having completed a PhD in Immunology, she started her commercial career in consultancy with McKinsey & Company in 1995 before moving to help establish Nexan Ltd, a medical device start-up. She has also worked in commercial roles at Acambis plc, a vaccine development company, and Cangene Corporation, an immune therapeutics company where she led Strategic Business Development from 2007-2011. Lindsey then worked as a freelance consultant, working with academic groups and companies across the biotech and pharmaceutical fields. In 2016 she joined Liminal Biosciences (previously known as Prometic), a Nasdaq listed multinational company focusing on rare diseases, where she was Senior Director of Business Development. At Liminal, she also managed major organisational changes, including steering the company's late-stage clinical programmes. Lindsey joins the Executive team at Arecor.
 
Sarah Howell, Chief Executive Officer of Arecor, said:  "We're thrilled that Lindsey is joining Arecor's Executive team as we enter our next phase of growth.  Lindsey will play a key role in ensuring that we deliver on the key strategic goals that we set out at the time of our recent IPO. She brings extensive experience from across the innovative healthcare sector which will significantly strengthen our commercial and operational capabilities as we advance our internal proprietary pipeline and further expand our partnered portfolio."
 
Lindsey Foulkes, of Arecor, said: "Arecor's innovative Arestat™ technology has been validated through multiple partnerships with major pharmaceutical and biotechnology companies, as well as through the best-in-class clinical data achieved for its lead insulin programme AT247. I'm excited to be joining the Company as it scales up and look forward to working with the team to deliver the benefits of Arecor's ability to enhance medicines to pharmaceutical partners and, ultimately, to patients."
 
-ENDS-
For more information, please contact:



Arecor Therapeutics plc


www.arecor.com




Dr Sarah Howell, Chief Executive Officer


Tel: +44 (0) 1223 426060
Email: info@arecor.com




 


 




Susan Lowther, Chief Financial Officer


Tel: +44 (0) 1223 426060
Email: info@arecor.com




 


 




Mo Noonan, Communications


Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com




 


 




Panmure Gordon (UK) Limited (NOMAD and Broker)


 




Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)


Tel: +44 (0) 20 7886 2500
 




 


 




Consilium Strategic Communications


 




Chris Gardner, David Daley, Angela Gray


Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com



 
 
Notes to Editors
 
About Arecor
Arecor Therapeutics plc is a biopharmaceutical company transforming patient care by bringing innovative medicines to market.  Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies.  Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
 
For further details please see our website, www.arecor.com
 
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRABKLLBFQLLBBB